Skip to main content

Advertisement

Table 2 Survival outcomes

From: S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial

  Intention to treat population Per-protocol population
SOX CapeOX Effect size (95% CI); p value SOX CapeOX Effect size (95% CI), p value
Number of patients 168 172   164 161  
Median PFS 7.1 (6.4-8.1) 6.3 (4.9-6.7) 0.83 (0.66-1.04), p = .10 6.9 (6.4-7.9) 6.3 (5.2-6.7) 0.84 (0.67-1.06), p = .13
Median OS 19.0 (15.3-23.0) 18.5 (14.1-20.8) 0.86 (0.68-1.08), p = .19 19.1 (15.0-23.0) 17.6 (14.1-20.5) 0.85 (0.67-1.08), p = .17
Number of patients 150 151   147 145  
Median PPS 9.3 (6.7-11.6) 9.5 (7.4-12.1) 0.97 (0.76-1.23), p = .81 9.3 (6.9-11.6) 9.6 (7.4-12.1) 0.96 (0.75-1.23), p = .75
  1. Data are represented as n (%), time in months (95% CI) or effect size (95% CI). SOX, S-1 plus oxaliplatin; CapeOX, Capecitabine plus oxaliplatin; PFS, progression-free survival; PPS, post-progression survival, OS = overall survival.